17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli

Journal of Leukocyte Biology

Volumn 90, Issue 3, 2011, Pages 459-470

  Palmer, Christine D ^a,b   Mancuso, Christy J ^a   Weiss, Jerrold P ^c   Serhan, Charles N ^b,d   Guinan, Eva C ^b,e   Levy, Ofer ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Eicosanoid; IL 6; Resolution of inflammation; TNF

Indexed keywords

CYTOKINE; DOCOSAHEXAENOIC ACID; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12P70; INTERLEUKIN 7; INTERLEUKIN 8; LIPID; LIPOXIN A; LIPOXIN B; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RESOLVIN; RESOLVIN D1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL INFECTION; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTERNALIZATION; MACROPHAGE; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOTTING, WESTERN; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; DOCOSAHEXAENOIC ACIDS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MUTATION; PHOSPHOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOLL-LIKE RECEPTOR 4;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MURINAE;

EID: 79960887646     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0311145     Document Type: Article

References (76)

1. Horwood, N. J., Page, T. H., McDaid, J. P., Palmer, C. D., Campbell, J., Mahon, T., Brennan, F. M., Webster, D., Foxwell, B. M. (2006) Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J. Immunol. 176, 3635-3641.
2. Hoshino, K., Takeuchi, O., Kawai, T., Sanjo, H., Ogawa, T., Takeda, Y., Takeda, K., Akira, S. (1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the LPS gene product. J. Immunol. 162, 3749-3752.
3. Palmer, C. D., Mutch, B. E., Workman, S., McDaid, J. P., Horwood, N. J., Foxwell, B. M. (2008) Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFκB activity. Blood 111, 1781-1788.
4. Serhan, C. N., Chiang, N., Van Dyke, T. E. (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8, 349-361.
5. Serhan, C. N., Savill, J. (2005) Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6, 1191-1197.
6. Schwab, J. M., Chiang, N., Arita, M., Serhan, C. N. (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447, 869-874.
7. Duffield, J. S., Hong, S., Vaidya, V. S., Lu, Y., Fredman, G., Serhan, C. N., Bonventre, J. V. (2006) Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 177, 5902-5911.
8. Godson, C., Mitchell, S., Harvey, K., Petasis, N. A., Hogg, N., Brady, H. R. (2000) Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164, 1663-1667.
9. Mitchell, S., Thomas, G., Harvey, K., Cottell, D., Reville, K., Berlasconi, G., Petasis, N. A., Erwig, L., Rees, A. J., Savill, J., Brady, H. R., Godson, C. (2002) Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J. Am. Soc. Nephrol. 13, 2497-2507.
10. Reville, K., Crean, J. K., Vivers, S., Dransfield, I., Godson, C. (2006) Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes. J. Immunol. 176, 1878-1888.
11. Gordon, S. (2003) Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23-35.
12. Gordon, S., Martinez, F. O. (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32, 593-604.
13. Salkowski, C. A., Neta, R., Wynn, T. A., Strassmann, G., van Rooijen, N., Vogel, S. N. (1995) Effect of liposome-mediated macrophage depletion on LPS-induced cytokine gene expression and radioprotection. J. Immunol. 155, 3168-3179.
14. Zarbock, A., Ley, K. (2009) Neutrophil adhesion and activation under flow. Microcirculation 16, 31-42.
15. Jonsson, S., Musher, D. M., Chapman, A., Goree, A., Lawrence, E. C. (1985) Phagocytosis and killing of common bacterial pathogens of the lung by human alveolar macrophages. J. Infect. Dis. 152, 4-13.
16. Klein, R. D., Su, G. L., Schmidt, C., Aminlari, A., Steinstraesser, L., Alarcon, W. H., Zhang, H. Y., Wang, S. C. (2000) Lipopolysaccharide-binding protein accelerates and augments Escherichia coli phagocytosis by alveolar macrophages. J. Surg. Res. 94, 159-166.
17. Poirier, K., Faucher, S. P., Beland, M., Brousseau, R., Gannon, V., Martin, C., Harel, J., Daigle, F. (2008) Escherichia coli O157:H7 survives within human macrophages: global gene expression profile and involvement of the Shiga toxins. Infect. Immun. 76, 4814-4822.
18. Hattori, M., Taylor, T. D. (2009) The human intestinal microbiome: a new frontier of human biology. DNA Res. 16, 1-12.
19. Sivick, K. E., Mobley, H. L. (2010) Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect. Immun. 78, 568-585.
20. Rolhion, N., Darfeuille-Michaud, A. (2007) Adherent-invasive Escherichia coli in inflammatory bowel disease. Inflamm. Bowel Dis. 13, 1277-1283.
21. Smith, A. M., Rahman, F. Z., Hayee, B., Graham, S. J., Marks, D. J., Sewell, G. W., Palmer, C. D., Wilde, J., Foxwell, B. M., Gloger, I. S., Sweeting, T., Marsh, M., Walker, A. P., Bloom, S. L., Segal, A. W. (2009) Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J. Exp. Med. 206, 1883-1897.
22. Andersen, B. M., Skjorten, F., Solberg, O. (1979) Electron microscopical study of Neisseria meningitidis releasing various amounts of free endotoxin. Acta Pathol. Microbiol. Scand. [B] 87B, 109-115.
23. Marshall, J. C., Walker, P. M., Foster, D. M., Harris, D., Ribeiro, M., Paice, J., Romaschin, A. D., Derzko, A. N. (2002) Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit. Care 6, 342-348.
24. Levy, O., Teixeira-Pinto, A., White, M. L., Carroll, S. F., Lehmann, L., Wypij, D., Guinan, E. (2003) Endotoxemia and elevation of lipopolysaccharide-binding protein after hematopoietic stem cell transplantation. Pediatr. Infect. Dis. J. 22, 978-981.
25. Fallach, R., Shainberg, A., Avlas, O., Fainblut, M., Chepurko, Y., Porat, E., Hochhauser, E. (2010) Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. J. Mol. Cell. Cardiol. 48, 1236-1244.
26. Tracey, K. J., Fong, Y., Hesse, D. G., Manogue, K. R., Lee, A. T., Kuo, G. C., Lowry, S. F., Cerami, A. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330, 662-664.
27. Cristofaro, P., Opal, S. M. (2006) Role of Toll-like receptors in infection and immunity: clinical implications. Drugs 66, 15-29.
28. Bahador, M., Cross, A. S. (2007) From therapy to experimental model: a hundred years of endotoxin administration to human subjects. J. Endotoxin Res. 13, 251-279.
29. Cross, A. S., Opal, S. M., Palardy, J. E., Drabick, J. J., Warren, H. S., Huber, C., Cook, P., Bhattacharjee, A. K. (2003) Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 21, 4576-4587.
30. Cross, A. S. (2010) Development of an anti-endotoxin vaccine for sepsis. Subcell. Biochem. 53, 285-302.
31. Cross, A. S., Opal, S., Cook, P., Drabick, J., Bhattacharjee, A. (2004) Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis. Vaccine 22, 812-817.
32. Gea-Banacloche, J. C., Opal, S. M., Jorgensen, J., Carcillo, J. A., Sepkowitz, K. A., Cordonnier, C. (2004) Sepsis associated with immunosuppressive medications: an evidence-based review. Crit. Care Med. 32, S578-S590.
33. Akashi, S., Nagai, Y., Ogata, H., Oikawa, M., Fukase, K., Kusumoto, S., Kawasaki, K., Nishijima, M., Hayashi, S., Kimoto, M., Miyake, K. (2001) Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. Int. Immunol. 13, 1595-1599.
34. Shimazu, R., Akashi, S., Ogata, H., Nagai, Y., Fukudome, K., Miyake, K., Kimoto, M. (1999) MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189, 1777-1782.
35. Borish, L. C., Steinke, J. W. (2003) 2. Cytokines and chemokines. J. Allergy Clin. Immunol. 111, S460-S475.
36. Bystrom, J., Evans, I., Newson, J., Stables, M., Toor, I., van Rooijen, N., Crawford, M., Colville-Nash, P., Farrow, S., Gilroy, D. W. (2008) Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood 112, 4117-4127.
37. Jones, S. A. (2005) Directing transition from innate to acquired immunity: defining a role for IL-6. J. Immunol. 175, 3463-3468.
38. Mosser, D. M., Edwards, J. P. (2008) Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969.
39. Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., Serhan, C. N. (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612-619.
40. Wu, S. H., Liao, P. Y., Yin, P. L., Zhang, Y. M., Dong, L. (2009) Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. Am. J. Pathol. 174, 115-122.
41. Morris, T., Stables, M., Hobbs, A., de Souza, P., Colville-Nash, P., Warner, T., Newson, J., Bellingan, G., Gilroy, D. W. (2009) Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 183, 2089-2096.
42. Kure, I., Nishiumi, S., Nishitani, Y., Tanoue, T., Ishida, T., Mizuno, M., Fujita, T., Kutsumi, H., Arita, M., Azuma, T., Yoshida, M. (2010) Lipoxin A(4) reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of NF-{κ}B activation. J. Pharmacol. Exp. Ther. 332, 541-548.
43. Zhang, L., Wu, P., Jin, S. W., Yuan, P., Wan, J. Y., Zhou, X. Y., Xiong, W., Fang, F., Ye, D. Y. (2007) Lipoxin A4 negatively regulates lipopolysaccharide-induced differentiation of RAW264.7 murine macrophages into dendritic-like cells. Chin. Med. J. (Engl.) 120, 981-987.
44. Zhou, X. Y., Wu, P., Zhang, L., Xiong, W., Li, Y. S., Feng, Y. M., Ye, D. Y. (2007) Effects of lipoxin A(4) on lipopolysaccharide induced proliferation and reactive oxygen species production in RAW264.7 macrophages through modulation of G-CSF secretion. Inflamm. Res. 56, 324-333.
45. Krishnamoorthy, S., Recchiuti, A., Chiang, N., Yacoubian, S., Lee, C. H., Yang, R., Petasis, N. A., Serhan, C. N. (2010) Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. USA 107, 1660-1665.
46. Ohira, T., Arita, M., Omori, K., Recchiuti, A., Van Dyke, T. E., Serhan, C. N. (2010) Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J. Biol. Chem. 285, 3451-3461.
47. El Kebir, D., Jozsef, L., Pan, W., Wang, L., Petasis, N. A., Serhan, C. N., Filep, J. G. (2009) 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am. J. Respir. Crit. Care Med. 180, 311-319.
48. Seki, H., Fukunaga, K., Arita, M., Arai, H., Nakanishi, H., Taguchi, R., Miyasho, T., Takamiya, R., Asano, K., Ishizaka, A., Takeda, J., Levy, B. D. (2010) The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J. Immunol. 184, 836-843.
49. Spite, M., Norling, L. V., Summers, L., Yang, R., Cooper, D., Petasis, N. A., Flower, R. J., Perretti, M., Serhan, C. N. (2009) Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461, 1287-1291.
50. Canny, G., Levy, O., Furuta, G. T., Narravula-Alipati, S., Sisson, R. B., Serhan, C. N., Colgan, S. P. (2002) Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc. Natl. Acad. Sci. U S A 99, 3902-3907.
51. Somerville Jr., J. E., Cassiano, L., Bainbridge, B., Cunningham, M. D., Darveau, R. P. (1996) A novel Escherichia coli lipid A mutant that produces an antiinflammatory lipopolysaccharide. J. Clin. Invest. 97, 359-365.
52. Vorachek-Warren, M. K., Ramirez, S., Cotter, R. J., Raetz, C. R. (2002) A triple mutant of Escherichia coli lacking secondary acyl chains on lipid A. J. Biol. Chem. 277, 14194-14205.
53. Reynolds, C. M., Raetz, C. R. (2009) Replacement of lipopolysaccharide with free lipid A molecules in Escherichia coli mutants lacking all core sugars. Biochemistry 48, 9627-9640.
54. Teghanemt, A., Zhang, D., Levis, E. N., Weiss, J. P., Gioannini, T. L. (2005) Molecular basis of reduced potency of underacylated endotoxins. J. Immunol. 175, 4669-4676.
55. Cui, W., Morrison, D. C., Silverstein, R. (2000) Differential tumor necrosis factor α expression and release from peritoneal mouse macrophages in vitro in response to proliferating gram-positive versus gram-negative bacteria. Infect. Immun. 68, 4422-4429.
56. Feldmann, M. (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2, 364-371.
57. József, L., Zouki, C., Petasis, N. A., Serhan, C. N., Filep, J. G. (2002) Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-κ B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc. Natl. Acad. Sci. USA 99, 13266-13271.
58. Palmer, C. D., Rahman, F. Z., Sewell, G. W., Ahmed, A., Ashcroft, M., Bloom, S. L., Segal, A. W., Smith, A. M. (2009) Diminished macrophage apoptosis and reactive oxygen species generation after phorbol ester stimulation in Crohn's disease. PLoS ONE 4, e7787.
59. Kurt-Jones, E. A., Popova, L., Kwinn, L., Haynes, L. M., Jones, L. P., Tripp, R. A., Walsh, E. E., Freeman, M. W., Golenbock, D. T., Anderson, L. J., Finberg, R. W. (2000) Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1, 398-401.
60. Yu, M., Wang, H., Ding, A., Golenbock, D. T., Latz, E., Czura, C. J., Fenton, M. J., Tracey, K. J., Yang, H. (2006) HMGB1 signals through Tolllike receptor (TLR) 4 and TLR2. Shock 26, 174-179.
61. Bustin, S. A. (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25, 169-193.
62. Cortés, G., Wessels, M. R. (2009) Inhibition of dendritic cell maturation by group A Streptococcus. J. Infect. Dis. 200, 1152-1161.
63. Nathe, K. E., Parad, R., Van Marter, L. J., Lund, C. A., Suter, E. E., Hernandez-diaz, S., Boush, E. B., Ikonomu, E., Gallington, L., Morey, J. A., Zeman, A. M., McNamara, M., Levy, O. (2009) Endotoxin-directed innate immunity in tracheal aspirates of mechanically ventilated human neonates. Pediatr. Res. 66, 191-196.
64. Moss, M. L., Jin, S. L., Becherer, J. D., Bickett, D. M., Burkhart, W., Chen, W. J., Hassler, D., Leesnitzer, M. T., McGeehan, G., Milla, M., Moyer, M., Rocque, W., Seaton, T., Schoenen, F., Warner, J., Willard, D. (1997) Structural features and biochemical properties of TNF-α converting enzyme (TACE). J. Neuroimmunol. 72, 127-129.
65. Sun, Y. P., Oh, S. F., Uddin, J., Yang, R., Gotlinger, K., Campbell, E., Colgan, S. P., Petasis, N. A., Serhan, C. N. (2007) Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem. 282, 9323-9334.
66. Liew, F. Y., Xu, D., Brint, E. K., O'Neill, L. A. (2005) Negative regulation of Toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5, 446-458.
67. Wu, S. H., Liao, P. Y., Dong, L., Chen, Z. Q. (2008) Signal pathway involved in inhibition by lipoxin A(4) of production of interleukins induced in endothelial cells by lipopolysaccharide. Inflamm. Res. 57, 430-437.
68. Oh, S. F., Pillai, P. S., Recchiuti, A., Yang, R., Serhan, C. N. (2011) Proresolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest. 121, 569-581.
69. Schif-Zuck, S., Gross, N., Assi, S., Rostoker, R., Serhan, C. N., Ariel, A. (2011) Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur. J. Immunol. 41, 366-379.
70. Haas-Stapleton, E. J., Lu, Y., Hong, S., Arita, M., Favoreto, S., Nigam, S., Serhan, C. N., Agabian, N. (2007) Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1. PLoS ONE 2, e1316.
71. Van Zoelen, M. A., Yang, H., Florquin, S., Meijers, J. C., Akira, S., Arnold, B., Nawroth, P. P., Bierhaus, A., Tracey, K. J., van der Poll, T. (2009) Role of Toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 31, 280-284.
72. Sfikakis, P. P. (2010) The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr. Dir. Autoimmun. 11, 180-210.
73. Arnold, T. M., Sears, C. R., Hage, C. A. (2009) Invasive fungal infections in the era of biologics. Clin. Chest Med. 30, 279-286 (vi.).
74. Palmer, C. D., Guinan, E., Levy, O. (2011) Deficient expression of baclericidal permeabllhty-increasing protein immunocompromised hosts: translational potential of replacement therapy. Biochem. Soc. Trans. In press.
75. Rahimi, R., Mozaffari, S., Abdollahi, M. (2009) On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig. Dis. Sci. 54, 471-480.
76. Ruggiero, C., Lattanzio, F., Lauretani, F., Gasperini, B., Andres-Lacueva, C., Cherubini, A. (2009) Omega-3 polyunsaturated fatty acids and immune-mediated diseases: inflammatory bowel disease and rheumatoid arthritis. Curr. Pharm. Des. 15, 4135-4148.